Eldorado Hotel & Spa Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2006



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer and Kinases: Lessons from the Clinic (C2)


Organizer(s) Brian J. Druker, Charles L. Sawyers and Kenneth W. Bair
February 14—19, 2006
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Abstract Deadline: Oct 13, 2005
Late Abstract Deadline: Nov 7, 2005
Scholarship Deadline: Oct 13, 2005
Early Registration Deadline: Dec 14, 2005

Part of the Translational Medicine Series, Sponsored by Pfizer Global Research & Development

Summary of Meeting:
Kinases are one of the most commonly mutated genes in cancer and numerous inhibitors of kinases involved in cancer are being tested in the clinic and many others are in development. Some such as imatinib (Gleevec) have been remarkably successful, while others have been much less successful. In addition, there have been significant improvements in the ability to synthesize specific kinase inhibitors. However, there remains a major need to understand the structural basis of compound selectivity, prospectively identify patients likely to respond to a kinase inhibitor, design improved pharmacodynamic endpoints, and understand the molecular basis of resistance to kinase inhibitor therapy. The goal of this meeting is to review the lessons learned from the successes and failures in the development and clinical application of kinase inhibitors to assist in more effective development and implementation of kinase inhibitors as therapeutic agents.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, FEBRUARY 14

15:00—19:30
Registration

Zia Concourse
18:30—19:30
Refreshments

Sunset Room
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
Axel Ullrich, Max Planck Institute of Biochemistry, Germany
From Paul Ehrlich's Dream of a 'Magic Bullet' to Multi-Targeted Cancer Therapy


WEDNESDAY, FEBRUARY 15

07:00—08:00
Breakfast

Eldorado Court
08:00—11:00
Identification of Kinases Targets
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
* Michael Stratton, Wellcome Trust Sanger Institute, UK
Sequencing of the Protein Kinase Gene Family in Human Cancers

William C. Hahn, Harvard Medical School, USA
Functional Approaches to Identify Kinase Targets in Cancer

Roberto D. Polakiewicz, Cell Signaling Technology, Inc., USA
Immunoafinity Profiling of Tyrosine Phosphorylation in Cancer Cells

Ronan C. O'Hagan, Merck Research Laboratories, USA
Short Talk: In vivo Genetic Approaches to Identify Mechanisms of Resistance to Inhibition of the HER2 Receptor Tyrosine Kinase

09:20—09:40
Coffee Break

Zia Concourse
11:00—13:00
Poster Setup

Sunset Room
13:00—22:00
Poster Viewing

Sunset Room
16:30—17:00
Coffee Available

Zia Concourse
17:00—19:00
Structural Chemistry of Kinases and Profiling Kinase Inhibitors
Meeting has ended...abstracts no longer viewable online.

* Stephen K. Burley, Rutgers University, USA
Fragment Based Drug Discovery for Oncology Targets

Isabelle S. Lucet, Monash University, Australia
Short Talk: The Structural Basis of Janus Kinase 2 Inhibition by a Potent and Specific Pan-Janus Kinase Inhibitor

Patrick Zarrinkar, Ambit Biosciences, USA
Understanding the Kinase Inhibitory Profiles of Drugs

Josephine Atienza, Takeda San Diego, USA
Short Talk: Development, Characterization and Validation of a High Content Label-Free and Real-Time Cell Based Kinase Assay Using a Microelectronic Sensor Array for Screening Selective and Potent Receptor Tyrosine Kinase Inhibitors

Tony Klink, Wisconsin Crop Improvement Association, USA
Short Talk: Simplifying Kinase Profiling Using ADP Detection Assay with the TranscreenerTM Kinase Assay

19:00—20:00
Social Hour with Lite Bites

Eldorado Court/Sunset Room
19:30—22:00
Poster Session 1

Sunset Room

THURSDAY, FEBRUARY 16

07:00—08:00
Breakfast

Eldorado Court
08:00—11:00
Example of Imatinib
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
* Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA
CML

Brian J. Skaggs, University of California, Los Angeles, USA
Short Talk: Biological and Biochemical Characterization of Imatinib and Dasatinib-Resistant BCR-ABL Mutants

Oliver Hantschel, Swiss Federal Institute of Technology Lausanne, Switzerland
Structural and Functional Insights into Bcr-Abl/c-Abl Regulation

Lukas C. Amler, Genentech, Inc., USA
Short Talk: Epithelial versus Mesenchymal Phenotype Determines in vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

09:20—09:40
Coffee Break

Zia Concourse
11:00—13:00
Poster Setup

Sunset Room
13:00—22:00
Poster Viewing

Sunset Room
16:30—17:00
Coffee Available

Zia Concourse
17:00—19:00
Recent Advancements in the Design of Pharmacodynamic Endpoints
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
David Piwnica-Worms, Washington University at St. Louis, USA
Pathway Specific Molecular Imaging Strategies

* Garry P. Nolan, Stanford University, USA
The Deeper Correlations: Kinases and Metabolism of Single Cells in Complex Populations

Gary A. Pestano, Ventana Medical Systems, USA
Tissue-Derived Diagnostic Biomarkers in the EGFR Over-Expression Pathway

19:00—20:00
Social Hour with Lite Bites

Eldorado Court/Sunset Room
19:30—22:00
Poster Session 2

Sunset Room

FRIDAY, FEBRUARY 17

07:00—08:00
Breakfast

Eldorado Court
08:00—11:00
EGFR and HER2 Targeted Therapy
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
Janet Dancey, National Cancer Institute, National Institutes of Health, USA
EGFR Inhibitors in Clinical Trials

* Daniel A. Haber, Massachusetts General Hospital, USA
EGFR Mutations in Sensitivity and Resistance to Tyrosine Kinase Inhibitors

Dennis J. Slamon, University of California, Los Angeles, USA
Update on HER2 Directed Therapy

Mark X. Sliwkowski, Genentech, Inc., USA
Structure of EGFR Family and Design of New HER-2 Antibodies

09:20—09:40
Coffee Break

Zia Concourse
16:30—17:00
Coffee Available

Zia Concourse
17:00—19:00
Receptor Tyrosine Kinases as Targets
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
* Donald Small, Johns Hopkins School of Medicine, USA
Targeting FLT3 for Novel Therapy of Leukemia

Paolo Michieli, University of Torino Medical School, Italy
Short Talk: Validating the Met tyrosine Kinase as a Target for Anti-Metastatic Therapy

Ross L. Cagan, Mount Sinai School of Medicine, USA
Short Talk: Drosophila Models for Metastasis and Lead Compound Screening

Jennifer Cain, Gilead, USA
Short Talk: TEL-PDGFRB-Induced Myeloproliferative Disease in Mice is Sensitive to Stat5a Gene Dosage

Yana Pikman, Harvard Medical School, USA
Short Talk: A Somatic Activating Mutation in the Thrombopoietin Receptor Leads to Activation of JAK-STAT Signaling in JAK2V617F-Negative Myelofibrosis with Myeloid Metaplasia

19:00—20:00
Social Hour with Lite Bites

Eldorado Court/Sunset Room

SATURDAY, FEBRUARY 18

07:00—08:00
Breakfast

Eldorado Court
08:00—11:00
Intracellular Kinase Targets
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
David Solit, Memorial Sloan Kettering Cancer Center, USA
Targeting Oncogenic B-Raf

Martin McMahon, University of California, San Francisco, USA
Short Talk: A New Mouse Model of BRAFV600E-Induced Tumorigenesis

Peter Lamb, Exelixis, USA
High Throughput Discovery of Spectrum-Selective PI3K Pathway Inhibitors

* D. Gary Gilliland, Merck & Co., Inc., USA
The Role of JAK2 in Myeloproliferative Disease

Helen Piwnica-Worms, Washington University School of Medicine, USA
Cdc25A/Chk1 Regulatory Pathway in Normal and Cancer Cell Cycles

09:20—09:40
Coffee Break

Zia Concourse
16:30—17:00
Coffee Available

Zia Concourse
17:00—18:30
Future of Kinase Targeted Therapies
Meeting has ended...abstracts no longer viewable online.

Anasazi Ballroom
Paul Workman, Institute of Cancer Research, UK
Drugging the Cancer Kinome: Optimising Combinatorial Therapeutic Strategies.

Dirk Mendel, KAI Pharmaceuticals, Inc., USA
Short Talk: Raf Kinase Inhibitor CHIR-265

* Kenneth W. Bair, Athelas Therapeutics, Inc., USA
New Paradigms for Kinase Inhibitor Development

18:30—19:30
Social Hour with Lite Bites

Eldorado Court/Sunset Room
18:30—21:30
Entertainment

Eldorado Court/Sunset Room

SUNDAY, FEBRUARY 19

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA117397-01




We gratefully acknowledge additional support for this conference from:

AVEO Pharmaceuticals, Inc. Cell Signaling Technology, Inc.
Educational donation provided by Amgen Novartis Institutes for BioMedical Research
Pfizer Global Research & Development
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Ambit Biosciences, Inc.


Cell Signaling Technology, Inc.


Chiron Corporation


Exelixis, Inc.


SGX Pharmaceuticals


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676